Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7714031 | 0.95 | SMN1; SMN2 (0.61) | SMN1; SMN2ALOX5LTA4HCYP4F2CYP4A11 | |
| SCHEMBL8993951 | 0.94 | SMN1; SMN2 (0.60) | SMN1; SMN2ALOX5LTA4HCYP4F2CYP4A11 | |
| SCHEMBL2405898 | 0.92 | SMN1; SMN2 (0.65) | SMN1; SMN2ALOX5LTA4HCYP4F2CYP4A11 | |
| SCHEMBL2762361 | 0.87 | SMN1; SMN2 (0.63) | SMN1; SMN2ALOX5LTA4HCYP4F2CYP4A11 | |
| SCHEMBL14570550 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2ALOX5LTA4HCYP4F2CYP4A11 | |
| SCHEMBL8993946 | 0.84 | CYP1A2 (0.46) | SMN1; SMN2ALOX5LTA4HCYP4F2CYP4A11 | |
| SCHEMBL2498213 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2ALOX5LTA4HCYP4F2CYP4A11 | |
| SCHEMBL30826512 | 0.83 | LTA4H (0.52) | SMN1; SMN2LTA4HALDH1A1 | |
| SCHEMBL13084328 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2ALOX5LTA4HCYP4F2CYP4A11 | |
| SCHEMBL20493705 | 0.83 | KMT2A (0.46) | SMN1; SMN2ALOX5LTA4HCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373890-A1 | DIBENZOXANTHENE QUENCHERS, USES, AND METHODS OF PREPARATION | Life Technologies Corporation (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024019017-A1 | REAGENT LAYER AND BIOSENSOR COMPRISING REAGENT LAYER | ＰＨＣホールディングス株式会社 | 2024-01-25 | — | — | WO | disclosed |
| WO-2023171473-A1 | ELECTRON ACCEPTOR, AND REAGENT LAYER AND SENSOR EACH USING SAME | ＰＨＣホールディングス株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2023004400-A1 | DIBENZOXANTHENE QUENCHERS, USES, AND METHODS OF PREPARATION | Life Technologies Corporation (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023004400-A1 | DIBENZOXANTHENE QUENCHERS, USES, AND METHODS OF PREPARATION | Life Technologies Corporation (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2019-10-31 | — | — | US | disclosed |
| US-5532171-A | PHENOTHIAZINE DYES FOR PHOTODYNAMIC THERAPY OF CANCER OR IMMUNOASSAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| US-5344928-A | Phenothiazine compounds for cancer treatment or immunoassay using chemiluminescence | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0510668-A2 | Phenothiazine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | NFATC1, EP300, CD69 | SMN1; SMN2 4829/4885ALOX5 1543/4885LTA4H 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.